Patents by Inventor Curtis A. Spilburg

Curtis A. Spilburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9107825
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: August 18, 2015
    Assignee: ZOMANEX, LLC
    Inventor: Curtis A. Spilburg
  • Publication number: 20150031628
    Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventor: Curtis A. Spilburg
  • Publication number: 20150030671
    Abstract: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventor: Curtis A. Spilburg
  • Publication number: 20110111009
    Abstract: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.
    Type: Application
    Filed: January 20, 2011
    Publication date: May 12, 2011
    Applicant: ZOMANEX LLC
    Inventor: CURTIS A. SPILBURG
  • Publication number: 20090088393
    Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.
    Type: Application
    Filed: September 28, 2007
    Publication date: April 2, 2009
    Applicant: ZOMANEX, LLC
    Inventor: CURTIS A. SPILBURG
  • Publication number: 20080124387
    Abstract: A method and composition of preparing bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, and solvent; mixing and then the solvent driven off; the ratios used differ from others, and maximize performance.
    Type: Application
    Filed: November 27, 2006
    Publication date: May 29, 2008
    Applicant: KAPAC, LLC
    Inventor: CURTIS A. SPILBURG
  • Patent number: 7071174
    Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: July 4, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
  • Publication number: 20060093661
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Application
    Filed: November 30, 2005
    Publication date: May 4, 2006
    Applicant: Kapac, LLC
    Inventor: Curtis Spilburg
  • Publication number: 20050244488
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol), lecithin or a sterol (stanol) derived ester, and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Application
    Filed: June 10, 2005
    Publication date: November 3, 2005
    Applicant: Kapac, LLC
    Inventor: Curtis Spilburg
  • Publication number: 20050153948
    Abstract: The present invention describes a composition that contains a plant sterol or plant stanol or their fatty acid esters and an emulsifier for treating conditions that are related to elevated dihydrotestosterone. The compositions can be prepared in a dry form for use as a food ingredient, tablet or capsule. Alternatively, the compositions can be dissolved in oil.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 14, 2005
    Applicant: Zomanex, LLC
    Inventor: Curtis Spilburg
  • Publication number: 20040047946
    Abstract: Use of polycosanols to lower egg cholesterol.
    Type: Application
    Filed: July 21, 2003
    Publication date: March 11, 2004
    Applicant: Kapac, LLC
    Inventor: Curtis A. Spilburg
  • Publication number: 20030212046
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol), lecithin or a sterol (stanol) derived ester, and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Application
    Filed: May 7, 2002
    Publication date: November 13, 2003
    Applicant: KAPAC, LLC
    Inventor: Curtis A. Spilburg
  • Patent number: 6632801
    Abstract: A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: October 14, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
  • Patent number: 5981299
    Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: November 9, 1999
    Assignee: CV Therapeutics, Inc.
    Inventors: Louis George Lance, III, Curtis A. Spilburg
  • Patent number: 5792832
    Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 11, 1998
    Inventors: Louis George Lange, III, Curtis A. Spilburg
  • Patent number: 5679375
    Abstract: This invention encompasses methods for inhibiting and/or treating gastric and duodenal ulcers by the administration of purified, high molecular weight sulfated polysaccharide compositions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 21, 1997
    Assignee: C.V. Therapeuctics
    Inventors: Curtis A. Spilburg, Louis G. Lange, Esam Z. Dajani
  • Patent number: 5624836
    Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 29, 1997
    Inventors: Louis G. Lange, III, Curtis A. Spilburg
  • Patent number: 5616570
    Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: April 1, 1997
    Inventors: Louis G. Lange, III, Curtis A. Spilburg
  • Patent number: 5521303
    Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: May 28, 1996
    Assignee: CV Therapeutics, Inc.
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
  • Patent number: 5492822
    Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme. A method for recovering a solution of purified human pancreatic cholesterol esterase having a molecular weight of about 100,000 daltons is disclosed. The 100,000 dalton fraction of human pancreatic cholesterol esterase is purified first, by preparing a solution of dialyzed human pancreatic cytosol containing the esterase and other proteins. Next, the solution is passed over a hydroxyapetite column and then eluted to yield all of the molecular weight fractions of the esterase and other proteins in the solution present as a single peak to give a first eluent.
    Type: Grant
    Filed: February 10, 1995
    Date of Patent: February 20, 1996
    Assignee: Louis G. Lange, III
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Paula M. Kinnunen